Mostafa Faisal: Donor Type and Long-Term Quality of Life After HCT for Severe Aplastic Anemia
Mostafa Faisal, Associate Professor of Clinical Hematology and HSCT at Assiut University, shared a post on X about a recent article by Matty Slaught et al., published in Transplantation and Cellular Therapy, adding:
“Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation.
Long-term SAA HCT survivors:
- 122 survivors; median 26 years after HCT
- 49% employed full-time, 24% part-time
- Common late effects: sexual dysfunction 35%, cataracts 20%, low bone density 20%
- 34% required antihypertensive therapy
Alternative-donor HCT associated with more musculoskeletal problems (OR 9.9)
SF-36 physical 49.5 and mental 49.9, essentially identical to population norms
No major QOL differences by donor type
Lifelong surveillance remains essential, but long-term QOL is reassuring.”
Title: Comparison of Late Effects and Quality of Life by Donor Type in Long-Term Survivors of Severe Aplastic Anemia after Hematopoietic Cell Transplantation
Authors: Matty Slaught, Lynn Onstad, Paul A. Carpenter, Sioban B. Keel, Catherine J. Lee, Shivaprasad Manjappa, Lauri Burroughs, Rohtesh S. Mehta, Masumi Ueda Oshima, Phuong Vo, K. Scott Baker, Stephanie J. Lee, Neel S. Bhatt

Other posts featuring Mostafa Faisal on Hemostasis Today.
-
Nov 21, 2026, 15:50Philip Osbak: Co-Editing a New Research Topic in Frontiers in Cardiovascular Medicine
-
Nov 21, 2026, 15:30Amin Marashi: How Does the Microbiome Trigger the Immune System to Suddenly Turn Against the Body’s Own Blood-Clotting Regulators?
-
Nov 21, 2026, 15:26Christina P.: Exploring Joint Involvement and Musculoskeletal Symptoms in Antiphospholipid Syndrome
-
Nov 21, 2026, 14:4410 Posts Not to Miss This Week
-
Nov 21, 2026, 14:21Two Emerging Mechanisms Linking Sickle Cell Disease to Thrombosis
-
Nov 21, 2026, 13:06Christine Faressa: Precision PRP and Platelet Biology in Musculoskeletal Care
-
Nov 21, 2026, 13:04Eyad Jamileh: Atrial Fibrillation – Bridging the Global Gaps in Diagnosis and Stroke Prevention
-
Nov 21, 2026, 12:49Thibault Veyron: Optimizing Bivalirudin Treatment in HIT
-
Nov 21, 2026, 12:44Paulus Kirchhof: Left Atrial Appendage Occlusion vs DOACs